Final Programme - iuphar

More documents

Recommendations

Info

FC09 Inflammation and immunopharmacology: New tools for old diseases Leaders: Salvador Moncada, (UK), Eeva Moilanen, (Finland), Ian Adcock,(UK) & Frans Nijkamp, (The Netherlands) FC09.1 Steroids and beyond: novel treatments for asthma and allergy Chairs: Ian Adcock, (UK) & Hiromasa Inoue, (Japan) 09:30 - 09:55 FC09.1.1 Improving current steroids Ian M Adcock, (UK) 09:55 - 10:20 FC09.1.2 The mast cell as a target for anti-asthma drugs Christian Taube, (Germany) 10:20 - 10:45 FC09.1.3 Effector and regulatory T cells in asthma Cezmi A Akdis, (Switzerland) 10:45 - 11:15 COFFEE BREAK 11:15 - 11:40 FC09.1.4 Suppressor of cytokine signaling in asthma Hiromasa Inoue, (Japan) 11:40 - 11:55 FC09.1.5 Free Communication Presentation: MAP kinase phosphatase-1 as a novel anti-inflammatory target Riku Korhonen, (Finland), R Nieminen, T Turpeinen, V Taimi, AR Clark, E Moilanen 11:55 - 12:10 FC09.1.6 Free Communication Presentation: Pitavastatin improves lung inflammation and survival in septic mice: prevention of reduced lung glucocorticoid receptors. Ken-ichi Takano, (Japan), S Yamamoto, K Tomita, H Yamazaki, H Yokoo, Y Takano, Y Hattori 38 Monday 19 July ■ 09:30 - 12:15 ■ Hall A2
IN PHARMACOLOGY �� ACADEMIC PUBLISHING IN THE 21 ST CENTURY �� FRONTIERS IN ANALYTICAL AND EXPERIMENTAL PHARMACOLOGY Martin Michel and Salvatore Salomone FRONTIERS IN BIOPHARMACY AND DRUG DELIVERY SYSTEMS Véronique Préat FRONTIERS IN CLINICAL TRIALS AND PHARMACOTHERAPY Filippo Drago FRONTIERS IN DRUG DISCOVERY Markus Follmann FRONTIERS IN DRUG METABOLISM AND TRANSPORT Jaime Kapitulnik FRONTIERS IN ETHNOPHARMACOLOGY Michael Heinrich FRONTIERS IN G PROTEIN-COUPLED RECEPTOR PHARMACOLOGY R A John Challiss FRONTIERS IN GASTROINTESTINAL PHARMACOLOGY Gareth J Sanger FRONTIERS IN INTEGRATIVE PHARMACOLOGY Jerry Buccafusco † FRONTIERS IN NEUROPHARMACOLOGY Nicholas M Barnes FRONTIERS IN PAIN PHARMACOLOGY Giustino Varrassi FRONTIERS IN PEDIATRIC CLINICAL PHARMACOLOGY Gérard Pons FRONTIERS IN PHARMACOECONOMICS AND HEALTH OUTCOMES Dominique Dubois FRONTIERS IN PHARMACOGENETICS Ulrich Zanger FRONTIERS IN PHARMACOLOGY OF ION CHANNEL AND CHANNELOPATHIES Philippe Lory and Diana Conte FRONTIERS IN PHARMACOLOGY OF NATURAL PRODUCTS Ding-Feng Su www.frontiersin.org FRONTIERS IN PHARMACOLOGY OF THROMBOSIS Bianca Rocca FRONTIERS IN PHARMACOTHERAPY OF CARDIOVASCULAR DISORDERS Eliot Ohlstein FRONTIERS IN PHARMACOTHERAPY OF INFLAMMATION Paola Patrignani FRONTIERS IN PHARMACOTHERAPY OF NEOPLASTIC DISEASES Olivier Feron FRONTIERS IN PREDICTIVE TOXICITY Olavi Pelkonen FRONTIERS IN SIGNAL TRANSDUCTION PHARMACOLOGY Vincent Laudet
Page 1: of basic and clinical pharmacology
Page 4 and 5: Congress patron 2 HRH Crown Princes
Page 6 and 7: Congress President Kim Brøsen Secr
Page 8 and 9: General information Registration &
Page 10 and 11: Banks, currency & credit cards The
Page 12 and 13: Information to presenters ■ The a
Page 14 and 15: Hotel Bella Center Copenhagen Groun
Page 16 and 17: Programme at a glance Time Hall A2
Page 18 and 19: 16 General events General events Op
Page 20 and 21: Programme outline Plenary lectures
Page 22 and 23: FC10 Drugs for half the world: Paed
Page 24 and 25: Tue 12:45 W13 Workshop: Novel perip
Page 26 and 27: W01 Pharmacology of adrenoceptors:
Page 28 and 29: W02 Symposium on advances in GI pha
Page 30 and 31: W04 Symposium: Antioxidants as ther
Page 32 and 33: Plenary lectures PL01 Plenary lectu
Page 34 and 35: FC02 Transmembrane transport: Persp
Page 36 and 37: FC04 Pharmacoepidemiology, current
Page 38 and 39: FC06 The heart gone wrong: Stabiliz
Page 42 and 43: W02 Symposium on advances in GI pha
Page 44 and 45: SS01 Sponsored symposium Sponsored
Page 46 and 47: W06 Workshop. Effect of disease on
Page 48 and 49: W08 Workshop. Identifying targets f
Page 50 and 51: W10 Workshop. Innovative Medicines
Page 52 and 53: FC01 Clinical pharmacology in the e
Page 54 and 55: FC03 Ion channels in analgesia and
Page 56 and 57: FC05 Translational science in the m
Page 60 and 61: FC08 Development in the treatment o
Page 62 and 63: Plenary lectures PL04 Plenary lectu
Page 64 and 65: FC01 Clinical pharmacology in the e
Page 66 and 67: FC03 Ion channels in analgesia and
Page 68 and 69: FC05 Translational science in the m
Page 70 and 71: FC07 Simulation and data modelling
Page 72 and 73: FC09 Inflammation and immunopharmac
Page 74 and 75: W12 Workshop. Experimental pain met
Page 76 and 77: W14 Workshop. Translating the human
Page 78 and 79: W15 Workshop. The IUPHAR initiative
Page 80 and 81: W17 Workshop. Standards for PhD Edu
Page 82 and 83: W19 Workshop. Influence of degenera
Page 84 and 85: FC02 Transmembrane transport: Persp
Page 86 and 87: FC04 Pharmacoepidemiology, current
Page 90 and 91:
FC08 Development in the treatment o
Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
Page 94 and 95:
FC10 Drugs for half the world: Paed
Page 96 and 97:
FC12 Ion channelopathies: New windo
Page 98 and 99:
FC14 Addiction and doping: Neurobio
Page 100 and 101:
FC17 New approaches and targets in
Page 102 and 103:
W04 Symposium: Antioxidants as ther
Page 104 and 105:
W21 Workshop. Inflammation - here,
Page 106 and 107:
W23 Workshop. Applying pharmacogeno
Page 108 and 109:
W25 Workshop. High science in the l
Page 110 and 111:
W27 Workshop. Approaches to medicin
Page 112 and 113:
FC11 G protein-coupled 7TM receptor
Page 114 and 115:
FC13 Maximising benefits and minimi
Page 116 and 117:
FC15 Endothelium in Health and dise
Page 118 and 119:
Page 120 and 121:
FC18 Nuclear receptor targets for t
Page 122 and 123:
PL16 Plenary Lecture Supported by a
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
FC15 Endothelium in Health and dise
Page 130 and 131:
Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
Page 134 and 135:
W30 Workshop. Is eNOS still a valid
Page 136 and 137:
W32 Workshop. The good, the bad and
Page 138 and 139:
W34 Workshop. State-of-the-art of b
Page 140 and 141:
FC10 Drugs for half the world: Pedi
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
FC16 Natural products: Past and fut
Page 148 and 149:
Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
FC15 Endothelium in health and dise
Page 158 and 159:
Page 160 and 161:
158
Page 162 and 163:
FC01 Clinical pharmacology in the e
Page 164 and 165:
Page 166 and 167:
FC02 Transmembrane transport: Persp
Page 168 and 169:
FC03 Ion channels in analgesia and
Page 170 and 171:
W12 Experimental pain methods in de
Page 172 and 173:
FC04 Pharmacoepidemiology, current
Page 174 and 175:
FC05 Translational science in the m
Page 176 and 177:
Page 178 and 179:
FC06 The heart gone wrong; stabiliz
Page 180 and 181:
FC07 Simulation and data modelling
Page 182 and 183:
FC08 Developments in the treatment
Page 184 and 185:
FC09 Inflammation and immunopharmac
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
W03 Targeting TRP channels for pain
Page 196 and 197:
W19 Influence of degeneration and r
Page 198 and 199:
W19 Influence of degeneration and r
Page 200 and 201:
W20 Pharmacology education for a su
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
FC04 Pharmacoepidemiology, current
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
FC06 The heart gone wrong; stabiliz
Page 216 and 217:
FC07 Simulation and data modelling
Page 218 and 219:
FC08 Developments in the treatment
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
FC19 General session Tue 361 Analge
Page 232 and 233:
FC19 General session - Biologics Tu
Page 234 and 235:
FC19 General session - Haematology
Page 236 and 237:
FC19 General session - oncology Tue
Page 238 and 239:
FC19 General session - oncology Tue
Page 240 and 241:
FC19 General session - Toxicology T
Page 242 and 243:
W02 Symposium on advances in GI pha
Page 244 and 245:
W11 New opportunities in the pharma
Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
W30 Is eNOS Still a valid therapeut
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
W34 State-of-the-art of basic and c
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
W29 New horizons in therapeutic dru
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
314 Index Name Paper ref. Name Pape
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
Page 384 and 385:
382 Notes Notes
Page 386:
Final Programme printed in Singapor
show all

Final Programme - iuphar

Create successful ePaper yourself

Delete template?

Save as template?